GBIO
Generation Bio Co
$
5.540
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
5.620
Open
5.620
VWAP
5.54
Vol
2.90K
Mkt Cap
37.87M
Low
5.540
Amount
16.09K
EV/EBITDA(TTM)
--
Total Shares
66.53M
EV
-51.76M
EV/OCF(TTM)
--
P/S(TTM)
1.91
Generation Bio Co. is a biotechnology company. The Company is engaged in developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. It focuses on autoimmune targets that have been undruggable or poorly drugged selectively in T cells. Its proprietary cell-targeted lipid nanoparticle (ctLNP) technology enables selective access to T cells and precise target inhibition by siRNA to selectively modulate T cells, blocking autoimmune tissue damage while sparing the broader immune system. Its proprietary stealth technology prevents its LNP from interacting with serum-binding proteins and reduces clearance by the liver and spleen to less than 1%, enabling potency and selectivity. Its selective delivery allows it to inhibit targets in T cells while sparing critical function in other cell types.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
0.00
-100%
-1.022
-67.23%
0.00
-100%
-1.065
-51.59%
550.00K
-86.87%
-2.187
-31.67%
Estimates Revision
The market is revising Upward the revenue expectations for Generation Bio Co. (GBIO) for FY2025, with the revenue forecasts being adjusted by 1.78% over the past three months. During the same period, the stock price has changed by -16.82%.
Revenue Estimates for FY2025
Revise Upward
+1.78%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-54.23%
In Past 3 Month
Stock Price
Go Down
-16.82%
In Past 3 Month
6 Analyst Rating
Wall Street analysts forecast GBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GBIO is 11.00 USD with a low forecast of 7.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
3 Hold
0 Sell
Moderate Buy
Current: 5.540
Low
7.00
Averages
11.00
High
15.00
Current: 5.540
Low
7.00
Averages
11.00
High
15.00
Canaccord
Buy
maintain
$9 -> $10
2025-08-18
Reason
Canaccord
Price Target
$9 -> $10
2025-08-18
maintain
Buy
Reason
Canaccord raised the firm's price target on Generation Bio to $10 from $9 and keeps a Buy rating on the shares. The firm said the company update included 2 key announcements. First, it announced new NHP data that shows siRNA delivery to T cells via the company's proprietary ctLNP platform; likely the first dataset of its kind. And also noted that it has developed siRNA candidates targeting LAT1 and VAV1, known targets in the autoimmune space.
Wedbush
Outperform -> Neutral
downgrade
$7
2025-08-13
Reason
Wedbush
Price Target
$7
2025-08-13
downgrade
Outperform -> Neutral
Reason
Wedbush downgraded Generation Bio to Neutral from Outperform with a $7 price target.
Wedbush
David Nierengarten
Outperform -> Neutral
downgrade
$7
2025-08-13
Reason
Wedbush
David Nierengarten
Price Target
$7
2025-08-13
downgrade
Outperform -> Neutral
Reason
As previously reported, Wedbush analyst David Nierengarten downgraded Generation Bio to Neutral from Outperform with a $7 price target. The firm notes the company reported earnings and announced a strategic restructuring, including a 90% reduction in workforce to be completed at the end of October. The company will maintain its core R&D capabilities during the initial phase of restructuring, including lead siRNAs targeting LAT1 and VAV1, and a ctLNP delivery system targeted toward T cells. Based on the indefinite postponement of lead candidate selection and development plans, Wedbush is moving to the sidelines as the company seeks strategic alternatives.
Needham
Gil Blum
Strong Buy
Reiterates
$8
2025-04-10
Reason
Needham
Gil Blum
Price Target
$8
2025-04-10
Reiterates
Strong Buy
Reason
Canaccord Genuity
Whitney Ijem
Strong Buy
Maintains
$9
2025-03-17
Reason
Canaccord Genuity
Whitney Ijem
Price Target
$9
2025-03-17
Maintains
Strong Buy
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$8
2025-03-14
Reason
Needham
Gil Blum
Price Target
$8
2025-03-14
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Generation Bio Co (GBIO.O) is -0.52, compared to its 5-year average forward P/E of -4.36. For a more detailed relative valuation and DCF analysis to assess Generation Bio Co 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.36
Current PE
-0.52
Overvalued PE
0.84
Undervalued PE
-9.56
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.09
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.82
Undervalued EV/EBITDA
-4.99
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
97.98
Current PS
5.62
Overvalued PS
257.56
Undervalued PS
-61.60
Financials
Annual
Quarterly
FY2025Q3
YoY :
-78.90%
1.59M
Total Revenue
FY2025Q3
YoY :
+92.63%
-32.20M
Operating Profit
FY2025Q3
YoY :
-63.95%
-5.52M
Net Income after Tax
FY2025Q3
YoY :
-64.19%
-0.82
EPS - Diluted
FY2025Q3
YoY :
+168.26%
-52.68M
Free Cash Flow
FY2025Q3
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q3
YoY :
+33.79%
-751.38
FCF Margin - %
FY2025Q3
YoY :
+70.84%
-346.30
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
2
203.2K
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 223.76% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
2
203.2K
USD
Months
GBIO News & Events
Events Timeline
2025-10-22 (ET)
2025-10-22
16:50:34
Generation Bio CEO McDonough Resigns; Howze Appointed Interim CEO
2025-07-18 (ET)
2025-07-18
08:36:08
Generation Bio announces 1-for-10 reverse stock split
2025-01-06 (ET)
2025-01-06
15:52:24
Generation Bio chief scientific officer Matthew Stanton to leave role
Sign Up For More Events
Sign Up For More Events
News
5.0
10-29NewsfilterCompass Pathways Names Dr. Jeffrey Jonas to Its Board of Directors
4.0
08-13BenzingaNeedham Reiterates Buy on Generation Bio, Maintains $15 Price Target
8.5
08-13BenzingaWhy Sapiens International Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket
Sign Up For More News
People Also Watch
FORA
Forian Inc
2.150
USD
0.00%
RGC
Regencell Bioscience Holdings Ltd
12.950
USD
-0.38%
KOSS
Koss Corp
4.800
USD
0.00%
SOTK
Sono-Tek Corp
4.400
USD
0.00%
MDBH
MDB Capital Holdings LLC
3.650
USD
+1.27%
TORO
Toro Corp
3.870
USD
-0.26%
IMRX
Immuneering Corp
6.500
USD
+0.78%
OSTX
OS Therapies Inc
1.810
USD
-0.55%
NSTS
NSTS Bancorp Inc
11.230
USD
+2.32%
INUV
Inuvo Inc
2.510
USD
-2.71%
FAQ
What is Generation Bio Co (GBIO) stock price today?
The current price of GBIO is 5.54 USD — it has decreased -1.42 % in the last trading day.
What is Generation Bio Co (GBIO)'s business?
What is the price predicton of GBIO Stock?
What is Generation Bio Co (GBIO)'s revenue for the last quarter?
What is Generation Bio Co (GBIO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Generation Bio Co (GBIO)'s fundamentals?
How many employees does Generation Bio Co (GBIO). have?